Cargando…
Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy
BACKGROUND: Two thrombopoietin receptor agonists (TPO-RA), romiplostim and eltrombopag, are currently widely adopted as second-line ITP therapy even in the absence of robust evidence on their comparative advantages over rituximab or splenectomy or their preferential use in some specific clinical con...
Autores principales: | Napolitano, Mariasanta, Vianelli, Nicola, Ghiotto, Lisanna, Cantoni, Silvia, Carli, Giuseppe, Carpenedo, Monica, Carrai, Valentina, Consoli, Ugo, Giuffrida, Gaetano, Lucchini, Elisa, Rossi, Elena, Santoro, Cristina, Rodeghiero, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000838/ https://www.ncbi.nlm.nih.gov/pubmed/36908864 http://dx.doi.org/10.4084/MJHID.2023.019 |
Ejemplares similares
-
P1635: REAL-WORLD DATA OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) USE IN IMMUNE THROMBOCYTOPENIA (ITP)
por: Dangudubiyyam, S., et al.
Publicado: (2022) -
Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic
por: Rodeghiero, Francesco, et al.
Publicado: (2021) -
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019) -
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists
por: Gilreath, Jeffrey, et al.
Publicado: (2021) -
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
por: Carpenedo, Monica, et al.
Publicado: (2021)